CVS Health Corporation (NYSE:CVS)‘s stock had its “hold” rating reissued by stock analysts at Loop Capital in a research note issued to investors on Friday, October 27th.
Other equities research analysts also recently issued reports about the company. BidaskClub upgraded CVS Health Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Citigroup Inc. decreased their price objective on CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating for the company in a report on Thursday, August 17th. Royal Bank Of Canada began coverage on CVS Health Corporation in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 price objective for the company. Jefferies Group LLC boosted their price objective on CVS Health Corporation from $82.00 to $86.00 and gave the company a “hold” rating in a report on Friday, September 15th. Finally, Wolfe Research downgraded CVS Health Corporation from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $89.00 to $82.00 in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company’s stock. CVS Health Corporation presently has a consensus rating of “Buy” and a consensus target price of $85.82.
CVS Health Corporation (NYSE:CVS) traded up $1.97 during trading hours on Friday, reaching $70.99. The company had a trading volume of 10,299,900 shares, compared to its average volume of 6,615,108. CVS Health Corporation has a fifty-two week low of $66.45 and a fifty-two week high of $84.72. The firm has a market capitalization of $71,720.00, a price-to-earnings ratio of 12.43, a PEG ratio of 1.22 and a beta of 0.86. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.
CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. CVS Health Corporation had a return on equity of 16.96% and a net margin of 2.77%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.64 earnings per share. sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/13/cvs-health-corporation-cvs-given-hold-rating-at-loop-capital.html.
In other news, Director Richard J. Swift sold 2,500 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total transaction of $199,050.00. Following the transaction, the director now directly owns 3,258 shares in the company, valued at approximately $259,401.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David M. Denton sold 237,078 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the sale, the chief financial officer now owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold a total of 716,625 shares of company stock worth $58,318,431 over the last quarter. Corporate insiders own 0.61% of the company’s stock.
A number of hedge funds have recently modified their holdings of CVS. CGOV Asset Management boosted its holdings in CVS Health Corporation by 0.3% during the 1st quarter. CGOV Asset Management now owns 1,148,337 shares of the pharmacy operator’s stock valued at $120,090,000 after acquiring an additional 3,466 shares during the period. Waldron LP lifted its holdings in CVS Health Corporation by 217.4% in the 1st quarter. Waldron LP now owns 10,633 shares of the pharmacy operator’s stock worth $835,000 after buying an additional 7,283 shares during the period. Klingenstein Fields & Co. LLC lifted its holdings in CVS Health Corporation by 108.2% in the 1st quarter. Klingenstein Fields & Co. LLC now owns 244,090 shares of the pharmacy operator’s stock worth $19,162,000 after buying an additional 126,864 shares during the period. Commerzbank Aktiengesellschaft FI lifted its holdings in CVS Health Corporation by 25.3% in the 1st quarter. Commerzbank Aktiengesellschaft FI now owns 106,922 shares of the pharmacy operator’s stock worth $8,393,000 after buying an additional 21,602 shares during the period. Finally, Webster Bank N. A. lifted its holdings in CVS Health Corporation by 0.9% in the 1st quarter. Webster Bank N. A. now owns 79,030 shares of the pharmacy operator’s stock worth $6,203,000 after buying an additional 673 shares during the period. Institutional investors own 82.04% of the company’s stock.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.